Schedule-dependent synergistic effects of 5-fluorouracil and selumetinib in KRAS or BRAF mutant colon cancer models

Improving Bioscience Research Reporting: The ARRIVE Guidelines for Reporting Animal Research

Carol Kilkenny, William J. Browne, Innes C. Cuthill et al. · PLoS Biology · 2010 · 7.3K citations · Full text

Medicine, Biomedical Sciences, Epidemiology +12

Improving bioscience research reporting: The ARRIVE guidelines for reporting animal research

Carol Kilkenny, William J. Browne, Innes C. Cuthill et al. · Journal of Pharmacology and Pharmacotherapeutics · 2010 · 6.3K citations · Full text

Medicine, Biomedical Sciences, Epidemiology +12

EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of <i>BRAF</i> -Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib

Ryan B. Corcoran, Hiromichi Ebi, Alexa B. Turke et al. · Cancer Discovery · 2012 · 1K citations · Full text

Medicine, Oncology, Pharmacology +17

Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial

Jeffrey R. Infante, Leslie A. Fecher, Gerald S. Falchook et al. · The Lancet Oncology · 2012 · 558 citations

Medicine, Pharmacokinetics, Pharmacology +11

Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in <i>BRAF</i> V600–Mutant Colorectal Cancer

Ryan B. Corcoran, Chloé E. Atreya, Gerald S. Falchook et al. · Journal of Clinical Oncology · 2015 · 512 citations · Full text

Medicine, Oncology, Pharmacology +17